Caris Life Sciences (CAI) Change in Receivables (2024 - 2026)

Caris Life Sciences' Change in Receivables history runs 3 years deep, the most recent figure standing at -$21.6 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 173.26% year-over-year to -$21.6 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $29.8 million, down 11.91% from the prior year.
• Change in Receivables slipped to -$21.6 million in Q1 2026 per CAI's latest filing, from $91.0 million in the prior quarter.
• Across five years, Change in Receivables topped out at $91.0 million in Q4 2025 and bottomed at -$29.1 million in Q2 2025.
• The 3-year median for Change in Receivables is -$7.9 million (2025), against an average of $3.6 million.
• Biggest YoY gain for Change in Receivables was 383.97% in 2025; the steepest drop was 1176.62% in 2025.
• Year by year, Change in Receivables stood at $18.8 million in 2024, then jumped by 383.97% to $91.0 million in 2025, then slumped by 123.76% to -$21.6 million in 2026.
• Per Business Quant, the three latest CAI Change in Receivables figures stand at -$21.6 million (Q1 2026), $91.0 million (Q4 2025), and -$24.2 million (Q3 2025).